Scarica l'app Stockscreener
3.42
4.27%
0.14
Dopo l'orario di chiusura:
3.49
0.07
+2.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.28
Aprire:
$3.37
Volume 24 ore:
352.30K
Relative Volume:
1.19
Capitalizzazione di mercato:
$112.58M
Reddito:
-
Utile/perdita netta:
$-12.48M
Rapporto P/E:
-8.7692
EPS:
-0.39
Flusso di cassa netto:
$-7.93M
1 W Prestazione:
+9.62%
1M Prestazione:
-34.48%
6M Prestazione:
+8.92%
1 anno Prestazione:
+52.00%
Intervallo 1D:
$3.24
$3.423
Intervallo di 1 settimana:
$3.085
$3.423
Portata 52W:
$2.07
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Nome
Anixa Biosciences Inc
Settore
Industria
Telefono
408-708-9808
Indirizzo
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Confronta ANIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.42 | 107.97M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Iniziato | Maxim Group | Buy |
| 2022-12-23 | Iniziato | Chardan Capital Markets | Buy |
| 2021-04-12 | Iniziato | H.C. Wainwright | Buy |
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
ETF Watch: Will Anixa Biosciences Inc. stock deliver better than expected guidanceJuly 2025 Short Interest & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Why Anixa Biosciences Inc. stock appeals to dividend seekersWeekly Earnings Recap & Stock Timing and Entry Methods - ulpravda.ru
What catalysts could drive Anixa Biosciences Inc. stock higherWeekly Trade Recap & Verified Entry Point Detection - ulpravda.ru
Why analysts upgrade Anixa Biosciences Inc. stockStock Buyback Updates & Low Risk Trading Portfolio - ulpravda.ru
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Anixa Biosciences (ANIX) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic - MSN
Anixa Biosciences Inc (NASDAQ:ANIX) Sees Significant Increase in Short Interest - MarketBeat
Anixa Biosciences director Titterton buys $8,820 in common stock - MSN
Anixa Biosciences (STU:CY71) EV-to-OCF : -12.38 (As of Dec. 28, 2025) - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Anixa Biosciences (FRA:CY71) EV-to-OCF : -12.43 (As of Dec. 22, 2025) - GuruFocus
Can Anixa Biosciences Inc. stock attract ESG capital inflowsMarket Sentiment Review & Low Drawdown Trading Techniques - Улправда
Is Anixa Biosciences Inc. stock gaining market shareEarnings Recap Report & AI Enhanced Trading Signals - Улправда
Why retail investors pile into Anixa Biosciences Inc. stock2025 Market Overview & Safe Capital Preservation Plans - Улправда
Is Anixa Biosciences Inc. (CY71) stock a buy for dividend portfolios2025 Macro Impact & Fast Exit Strategy with Risk Control - DonanımHaber
ANIX: Phase 1 Breast Cancer Vaccine Success Paves Way for Program Advancement - Smartkarma
Will Anixa Biosciences Inc. stock deliver better than expected guidanceJuly 2025 Selloffs & Capital Protection Trade Alerts - DonanımHaber
Gap Down: Is Anixa Biosciences Inc CY71 stock cheap by valuation metricsNew Guidance & Target Return Focused Stock Picks - moha.gov.vn
What is the fair value of Anixa Biosciences Inc. stock now2025 EndofYear Setup & Fast Gain Swing Alerts - Улправда
How strong is Anixa Biosciences Inc. stock balance sheetWeekly Profit Summary & Growth Focused Stock Pick Reports - Улправда
Aug Action: Why Anixa Biosciences Inc stock could be next big winnerMarket Movers & Fast Momentum Entry Tips - moha.gov.vn
Anixa Biosciences Inc (ANIX) director reports 16,000 share option exercise - Stock Titan
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic - Investing.com Australia
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo Finance
ANIX: Breast cancer vaccine phase I showed 75% robust immune response and strong safety profile - TradingView — Track All Markets
Anixa Biosciences falls on phase 1 data for breast cancer vaccine - MSN
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 - WV News
Cleveland Clinic transfers breast cancer vaccine IND to Anixa - marketscreener.com
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine Developm - GuruFocus
Anixa Biosciences Announces Transfer of IND for Breast Cancer Va - GuruFocus
Anixa Biosciences takes over breast cancer vaccine IND from Cleveland Clinic By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic - Nasdaq
D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq
Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine D - GuruFocus
Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital - MarketBeat
ANIX: D. Boral Capital Maintains Buy Rating with $10 Price Targe - GuruFocus
Anixa Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Anixa Biosciences Inc Announces Positive Phase 1 Data for Breast Cancer Vaccine - TradingView — Track All Markets
Anixa Biosciences Says Breast Cancer Vaccine Candidate Meets Key Endpoints in Phase 1 Trial - marketscreener.com
Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why - Benzinga
Anixa Biosciences Announces Positive Phase 1 Data for Investigat - GuruFocus
Anixa Biosciences (ANIX) Presents Promising Phase 1 Breast Cance - GuruFocus
Anixa Biosciences (NASDAQ: ANIX) presents final Phase 1 breast cancer vaccine data - Stock Titan
Anixa’s breast cancer vaccine shows positive Phase 1 results - Investing.com
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants - WV News
Cleveland Clinic Presents Final Results of Phase 1 Clinical Trial of Preventive Breast Cancer Vaccine Study - Cleveland Clinic Newsroom
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Anixa Biosciences (NASDAQ: ANIX) sets Dec. 15 talk on Phase 1 breast cancer vaccine - Stock Titan
Anixa Biosciences (NASDAQ: ANIX) unveils final Phase 1 breast cancer vaccine results at 2025 SABCS - Stock Titan
Anixa Biosciences Inc Azioni (ANIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):